Press Room

ECA Conference: Spray Drying - Solutions for Pharmaceutical Industry

Start
Thursday, June 09, 2016 - 00:00
End
Thursday, June 09, 2016 - 00:00
Location: Loures, Portugal

In this three days conference dedicated to Spray Drying solutions, on the last day attendees have the opportunity to take advantage of an exclusive hands-on training. For that purpose several spray dryers are available at Hovione.

Hovione hosts a hands-on spray drying session in its site in Loures

Our experts provide an intensive experience and directly applicable know-how.

 
Hightlights:
  • how scale-up is done through mathematical modelling and how to take advantage
  • of scale-up to significantly improve powder properties.
  • how to develop a process under QbD, how to optimise production parameters and how to proceed
  • a scale-up from laboratory to industrial scale.
  • how to analyse and evaluate your product.
  • pratical exercise: having the chance to spray dry a material both at lab and commercial scale.
For more details about our tecnhologies contact us

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026